새롭게 진단된 비만한 제2형 당뇨병 환자에서 Voglibose와 Glimepiride로 치료한 경우 복부 비만 및 대사적 이상에 미치는 영향에 대한 임상 비교

Abstract

Background: To compare the effects of voglibose and glimepiride on adipose tissue and metabolic abnormalities in obese patients with newly diagnosed type 2 diabetes. Methods: Total of 40 obese patients with newly diagnosed type 2 diabetes (BMI > 25 ㎏/㎡) were included in this study. Study patients were randomized into voglibose group (n = 20) and glimepiride group (n = 20), where respective medication was administered for 12 weeks. We assessed the changes of biochemical parameters, body composition and serum adiponectin levels. Results: The voglibose treated group achieved a significant decrease in BMI, total body fat mass, and percent body fat (P < 0.05) after 12 weeks. A reduction in both subcutaneous and visceral abdominal adipose tissue area and VSR (visceral fat area/subcutaneous fat area) were noted only in the voglibose group (P < 0.05). Serum lipid profiles were similar between the two groups, except for the decrease in triglyceride levels, which were significant only in the voglibose group (P < 0.05). Serum adiponectin levels were increased only in the voglibose group (P < 0.05). Conclusions: In this study, voglibose showed to significantly decrease adipose tissue and improve adiponectin level.